Diagnosis of severe congenital A1-PI deficiency who have clinically evident emphysema, weight, A1-PI phenotype, A1-PI baseline level
|
|
- Shanna Ryan
- 5 years ago
- Views:
Transcription
1 AAT DEFICIENCY Aralast NP intravenous recon soln 1,000 Prolastin-C intravenous recon soln mg Zemaira Glassia Other Diagnosis of severe congenital A1-PI deficiency who have clinically evident emphysema, weight, A1-PI phenotype, A1-PI baseline level Prescription must be written by a pulmonologist 6 months for initiation, 1 year for continuation 1
2 ADAPALENE adapalene topical cream adapalene topical gel 0.1 % Other Not approved when used to treat photo aging. Diagnosis, previous treatments, and response therapy 1 year Must have failure, intolerance, or contraindication to tretinoin 2
3 ADEMPAS Adempas Other Confirmation of diagnosis, documentation of response to any prior therapies Prescription must be written by pulmonologist or cardiologist 3 months initial, 1 year continuation For WHO Group 1 diagnosis, patient must have a history of taking or contraindication to sildenafil (Revatio). 3
4 AFINITOR Afinitor Afinitor Disperz Other DIAGNOSIS, PRIOR THERAPIES, AND TREATMENT RESPONSE PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST OR NEUROLOGIST 3 MONTHS INITIAL, 1 YEAR CONTINUATION IN PATIENTS WITH RCC, USE OF AFINITOR IS RESERVED FOR THOSE WITH A DOCUMENTED TREATMENT FAILURE WITH NEXAVAR OR SUTENT 4
5 AIMOVIG Aimovig Autoinjector (2 Pack) Other Diagnosis, other therapies tried, and outcome. Member has been evaluated for and does not have medication overuse headache. 18 years of age or older Must be prescribed by or in consultation with a neurologist or pain specialist 1 year Patient must have an inadequate response, contraindication, or intolerance to two different chronic migraine prevention drugs. The two prerequisite drugs must be from different classes such as anticonvulsants (topiramate/valproate), beta blockers (propranolol, metoprolol), and antidepressants (nortriptyline/venlafaxine). 5
6 ALK POSITIVE TYROSINE KINASE INHIBITORS Alecensa Zykadia Xalkori Other Diagnosis, other treatments tried and outcome Prescribed by an oncologist 1 year 6
7 ALUNBRIG Alunbrig Other Non-small cell lung cancer (NSCLC): Diagnosis of metastatic NSCLC. Patient has an anaplastic lymphoma kinase (ALK)-positive tumor as detected with an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility. Trial and failure or intolerance to Xalkori (crizotinib). Prescribed by or in consultation with an oncologist 3 months initial, 6 months continuation Approve for continuation of prior therapy. 7
8 AMITIZA Amitiza Other DIAGNOSIS, DOCUMENTED FAILURE OF 2 OF THE FOLLOWING AGENTS: FIBER PRODUCT, POLYETHYLENE GLYCOL, LACTULOSE, DOCUSATE, OR BISACODYL 1 YEAR 8
9 AMPYRA Ampyra Other NOT A COVERED BENEFIT IN PATIENTS WITH SEIZURE DISORDER OR A CREATININE CLEARANCE LESS THAN 50 ML/MIN EXPANDED DISABILITY SCALE SCORE, BASELINE AND FOLLOW-UP 25 FOOT WALK TEST, CREATININE CLEARANCE PRESCRIPTION MUST BE WRITTEN BY A NEUROLOGIST 3 MONTHS INITIAL, 1 YEAR CONTINUATION PATIENT MUST SHOW AN IMPROVEMENT IN WALKING SPEED TO CONTINUE TREATMENT 9
10 ANTIDEPRESSANTS Fetzima Viibryd oral tablets,dose pack 10 mg (7)- Trintellix 20 mg (23) Viibryd oral tablet DIAGNOSIS, PRIOR THERAPIES TRIED AND FAILED 1 YEAR Other MUST SEE CONTRAINDICATION TO OR FAILURE OF 2 DIFFERENT CLASSES OF GENERIC ANTIDEPRESSANTS INCLUDING SSRIS, SNRIS, TCAS, NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS, OR NORADRENERGIC AND SPECIFIC SEROTONERGIC ANTIDEPRESSANTS 10
11 ANTIPSYCHOTICS Abilify Maintena aripiprazole oral solution aripiprazole oral tablet aripiprazole oral tablet,disintegrating Aristada Aristada Initio chlorpromazine oral clozapine oral tablet,disintegrating 100 mg, 12.5 mg, 25 mg clozapine oral tablet,disintegrating 150 mg, 200 mg Fanapt fluphenazine decanoate Versacloz 50mg/ml suspension fluphenazine HCl injection Invega Sustenna Invega Trinza Latuda paliperidone oral tablet extended release 24hr 1.5 mg, 3 mg, 6 mg, 9 mg quetiapine oral tablet extended release 24 hr Rexulti Saphris thioridazine Vraylar chlorpromazine 25mg/ml ampule Other FOR BIPOLAR DISORDER OR SCHIZOPHRENIA, DOCUMENTATION OF DIAGNOSIS, TREATMENT FAILURE WITH TWO ATYPICAL ANTIPSYCHOTICS (ZIPRASIDONE, RISPERIDONE, QUETIAPINE, OLANZAPINE, CLOZAPINE), OR RATIONALE AS TO WHY ALTERNATIVES ARE NOT SUITABLE 1 YEAR 11
12 ANTI-TNF ALPHA DRUGS Cimzia Cimzia Powder for Reconst Enbrel Enbrel SureClick Humira Humira Pediatric Crohns Start Humira Pen Humira Pen Crohns-UC-HS Start Humira Pen Psor-Uveits-Adol HS Humira(CF) Humira(CF) Pedi Crohns Starter Humira(CF) Pen Crohns-UC-HS Humira(CF) Pen Psor-Uv-Adol HS Humira(CF) Pen subcutaneous pen injector kit 40 mg/0.4 ml Simponi subcutaneous syringe Other DIAGNOSIS AND OTHER THERAPIES TRIED AND FAILED, NEGATIVE TB TEST MUST BE WRITTEN BY A DERMATOLOGIST, RHEUMATOLOGIST, GASTROENTEROLOGIST, OR OPHTHALMOLOGIST 3 MONTHS INITIAL, 1 YEAR CONTINUATION PRIOR TO RECEIVING BIOLOGIC THERAPY: FOR RHEUMATOID ARTHRITIS, PATIENT MUST HAVE A DOCUMENTED FAILURE WITH AT LEAST ONE DMARD. FOR CROHN'S DISEASE, PATIENT MUST HAVE A DOCUMENTED FAILURE WITH AT LEAST ONE NON-BIOLOGIC CONVENTIONAL THERAPY (INCLUDING BUT NOT LIMITED TO SULFASALAZINE, MESALAMINE, AZATHIOPRINE, OR METHOTREXATE). FOR PSORIASIS, PATIENT MUST HAVE TRIAL OF OR CONTRAINDICATION TO TOPICAL THERAPY AND METHOTREXATE. IN ORDER TO RECEIVE CIMZIA, SIMPONI, OR INFLIXMAB, PATIENT MUST HAVE A TRIAL OF OR CONTRAINDICATION TO ENBREL OR 12
13 HUMIRA, WITH THE EXCEPTION OF INFLIXIMAB FOR FISTULIZING CROHN'S DISEASE AND ULCERATIVE COLITIS 13
14 ARANESP Aranesp (in polysorbate) injection solution Aranesp (in polysorbate) injection syringe 100 mcg/ml, 200 mcg/ml, 25 mcg/ml, 300 mcg/ml, 40 mcg/ml, 60 mcg/ml Other Ucontrolled hypertension. Pure red cell aplasia that begins after ESA treatment. Pre-treatment hemoglobin level less than 10 g/dl AND Patient has adequate iron stores prior to initiation of therapy defined as ferritin more than 100 mcg/l or serum transferrin saturation greater than 20% AND other causes of anemia such as iron deficiency, folate deficiency or B12 deficiency, hemolysis, gastrointestinal bleeding, other active or occult bleeding, or underlying hematologic disease (such as sickle cell anemia, thalassemia, and porphyria) have been ruled out. CKD - prescribed by a nephrologist or hematologist. Non-myeloid malignancies - prescribed by an oncologist/hematologist Initial: 3 months. Renewal: CKD-12 months, Non-myeloid malignancies - 4 months For renewal of CKD, for dialysis patients: Hb less than 11 g/dl or physician will decrease or interrupt dose and for non-dialysis patients: Hb less than 10 g/dl or physician will decrease or interrupt dose. For renewal of non-myeloid malignancies: Concurrent myelosuppressive chemotherapy and Hb is 12g/dL or less and there is measurable response after eight weeks (defined as an increase in Hb 1 g/dl or more or a reduction in red blood cell transfusion requirements). 14
15 ARCALYST Arcalyst Other 12 YEARS AND OLDER 1 YEAR AT A TIME 15
16 BENLYSTA Benlysta subcutaneous syringe Other Severe active lupus nephritis, active central nervous, use in combination with other biologics Diagnosis, autoantibody testing, prior treatments including response, and SLEDAI score. must be 18 and older Prescription must be written by a rheumatologist 6 months Failed to demonstrate adequate response to TWO standard therapies at recommended doses: corticosteroids, antimalarials, NSAIDs, and/or immunosuppressants. SLEDAI score greater than 8. 16
17 BOSULIF Bosulif oral tablet 100 mg, 400 mg, 500 mg Other Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to bosutinib. CBC and LFT lab test results are needed for continuation treatment. Prescription must be written by an oncologist 1 year 17
18 BRAFTOVI Braftovi Other Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment. Prescription must be written by an oncologist 3 months for initiation, 1 year for continuation 18
19 CABOMETYX Cabometyx Other Renal cell carcinoma (RCC): Diagnosis of RCC. RCC is advanced. History of failure, contraindication, or intolerance to at least one prior antiangiogenic therapy [e.g., Nexavar (sorafenib), Sutent (sunitinib)]. Prescribed by or in consultation with an oncologist. 3 months initiation and 1 year continuation 19
20 CALQUENCE Calquence Other NA Documentation of diagnosis, previous treatments, and response to treatment. Prescribed by oncology 3 months initial, 6 months continuation 20
21 CAPRELSA Caprelsa oral tablet 100 mg, 300 mg Other HISTORY OF CONGENITAL LONG QT SYNDROME DIAGNOSIS, PRIOR THERAPIES, TREATMENT RESPONSE 18 YEARS AND OLDER PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST 3 MONTHS FOR INITIATION, 6 MONTHS FOR CONTINUATION ECG, ELECTROLYTE(K,Mg,Ca), AND TSH MONITORING AT BASELINE, 2-4 WEEKS AND 8-12 WEEKS AFTER STARTING TREATMENT AND EVERY 3 MONTHS THEREAFTER 21
22 CINQAIR Cinqair Other Administration of reslizumab requires a specialized care setting and requires an experienced clinician prepared to manage anaphylaxis will not be approved for self-administration Allergen test, baseline FEV1, FEV1 following bronchodilator, asthma medical history (including medications, emergency department visits, and hospitalizations), baseline eosinophil count Pulmonology or Immunologist 1 year Patient must be diagnosed with severe asthma, currently receiving inhaled and/or oral corticosteroid treatment, have a baseline eosinophil count of 400/mcL, have a contraindication, intolerance or failure of Nucala. 22
23 COMETRIQ Cometriq Other Diagnosis, prior therapy used, result of prior therapy. Prescription must be written by an oncologist 3 months for initiation, 6 months for continuation 23
24 COPIKTRA Copiktra Other Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment. Prescription must be written by an oncologist or hematologist 3 months for initiation, 1 year for continuation 24
25 CORLANOR Corlanor Other Ejection fraction less than or equal to 35% AND heart rate greater than 70 beats per minute AND in sinus rhythm AND on maximally tolerated betablocker OR has contraindication to beta-blocker (i.e.. allergy, severe COPD limiting beta blocker usage) Prescribed by a cardiologist. 12 months 25
26 COTELLIC Cotellic Other Diagnosis, other therapies tried and/or failed, and treatment response. Prescribed by an oncologist. 3 months for initiation, 6 months for continuation 26
27 DALIRESP Daliresp Diagnosis, prior therapies used and response to therapy, FEV1, baseline and follow-up weight assessments, baseline psychiatric evaluation Prescription must be written by pulmonologist or have had a pulmonology consult within the past 6 months 1 year Other To qualify for use, patients must have severe COPD (FEV1 less than 50% predicted) with a chronic bronchitis component and a history of exacerbations. Patients must also have concurrent use of long-acting bronchodilator and inhaled corticosteroid 27
28 DAURISMO Daurismo Other Diagnosis, prior therapies, and result of prior therapy. Prescription must be written by an oncologist or hematologist 1 year 28
29 DEMSER Demser Other Diagnosis and whether the patient is a candidate for surgery 3 months 29
30 DICLOFENAC GEL 3% diclofenac sodium topical gel 3 % Other Diagnosis and any prior treatments. Prescription must be written by a Dermatologist 3 months 30
31 DOPTELET Doptelet (10 tab pack) Doptelet (15 tab pack) Other Diagnosis and platelet count Must be prescribed by a hematologist, oncologist, or gastroenterologist 1 month Patient must be scheduled to undergo a pre planned medical or dental procedure with treatment beginning 10 to 13 days prior to the scheduled procedure. Patients should undergo their procedure 5 to 8 days after the last dose. 31
32 EGRIFTA Egrifta subcutaneous recon soln 1 mg Other ONLY APPROVED FOR PATIENTS WITH HIV ASSOCIATED LIPODYSTROPHY. NOT INDICATED FOR WEIGHT MANAGEMENT. DIAGNOSIS, BASELINE WAIST CIRCUMFERENCE, BASELINE IGF- 1 FASTING PLASMA GLUCOSE, AND BASELINE HGAIC. MONITORING EVERY 6 MONTHS OF PARAMETERS LISTED ABOVE. MUST NOT HAVE AN ACTIVE MALIGNANCY PRESCRIPTION MUST BE WRITTEN BY AN INFECTIOUS DISEASE SPECIALIST OR ENDOCRINOLOGIST 3 MONTHS 32
33 EMEND aprepitant For use with highly and moderately-emetogenic chemotherapy, provide the chemotherapy regimen including drug, dose, and frequency. Ondansetron is preferred for post-operative nausea/vomiting (PONV) prophylaxis. When Emend or aprepitant is used for PONV prophylaxis, provide rationale as to why ondansetron is not a suitable alternative. 6 months Other Drug will also be reviewed for coverage under part B versus part D. 33
34 ENTRESTO Entresto Other History of angioedema related to previous ACE inhibitor or ARB therapy, concomitant use with aliskiren, pregnancy Patient has a diagnosis of New York Heart Association class II to IV heart failure, reduced ejection fraction less than or equal to 40%, other therapies tried, and outcome Prescription must be written by a cardiologist OR patient must have a consultation with a cardiologist within the past 12 months. 1 year Trial of or contraindication to ONE ACE inhibitor AND receiving concomitant therapy with one of the following beta blockers: carvedilol, bisoprolol, sustained-release metoprolol, unless unable to tolerate or contraindicated AND patient will discontinue use of any concomitant ACE inhibitor or ARB before initiating therapy. 34
35 EPIDIOLEX Epidiolex Other Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment. Prescription must be written by or in consultation with a neurologist 1 year Monitor for hepatocellular injury in accordance with FDA approved label. For Lennox-Gastaut syndrome must have a failure, contraindication, or intolerance to lamotrigine and topiramate. 35
36 EPOETIN ALFA Epogen injection solution 2,000 unit/ml, Procrit injection solution 10,000 unit/ml, 20,000 unit/2 ml, 20,000 unit/ml, 3,000 2,000 unit/ml, 20,000 unit/ml, 3,000 unit/ml, 4,000 unit/ml unit/ml, 4,000 unit/ml, 40,000 unit/ml Other Uncontrolled hypertension. Pure red cell aplasia that begins after ESA treatment. Pre-treatment hemoglobin level less than 10 g/dl AND Patient has adequate iron stores prior to initiation of therapy defined as ferritin more than 100 mcg/l or serum transferrin saturation greater than 20% AND other causes of anemia such as iron deficiency, folate deficiency or B12 deficiency, hemolysis, gastrointestinal bleeding, other active or occult bleeding, or underlying hematologic disease (such as sickle cell anemia, thalassemia, and porphyria) have been ruled out. CKD - prescribed by a nephrologist or hematologist. Non-myeloid malignancies - prescribed by an oncologist/hematologist. Surgery - Prescribed by a surgeon. HIV - Prescribed by an infectious disease specialist. Initial: 3 months. Renewal: CKD-12 months, Non-myeloid cancers, HIV-4 months. Surgery-3 months For renewal of CKD, for dialysis patients: Hb less than 11 g/dl or physician will decrease or interrupt dose and for non-dialysis patients: Hb less than 10 g/dl or physician will decrease or interrupt dose. For renewal of non-myeloid malignancies: Concurrent myelosuppressive chemotherapy and Hb is 12g/dL or less and there is measurable response after eight weeks (defined as an increase in Hb 1 g/dl or more or a reduction in red blood cell transfusion requirements). For renewal of zidovudine-treated HIV, Hb is 12g/dL or less AND Zidovudine dose remains 4,200 mg/week or less and there is a measurable response after eight weeks (defined as an increase in Hb or a reduction in RBC transfusion requirements or documented dose escalation [up to max of 300 units/kg/dose]) 36
37 37
38 ERIVEDGE Erivedge Other PATIENTS WHO ARE CANDIDATES FOR SURGERY OR RADIATION DIAGNOSIS, PRIOR TREATMENTS, RESPONSE TO THERAPY 18 YEARS OF AGE AND OLDER PRESCRIPTION MUST BE WRITTEN BY A ONCOLOGIST OR DERMATOLOGIST 3 MONTHS FOR INITIATION, 6 MONTHS FOR CONTINUATION 38
39 ERLEADA Erleada Other Diagnosis, other therapies tried and outcome, fall risk assessment, and seizure history (if any) Must be prescribed by an oncologist or urologist 1 year 39
40 EXJADE Exjade Other myelodysplastic syndrome, renal failure, and neoplastic disease Serum ferritin, CrCl, serum transaminases and bilirubin, baseline auditory and ophthalmic examinations. For Non-Transfusion-Dependent Thalassemia Syndromes: liver iron concentration (LIC) by liver biopsy or by an FDA-cleared or approved method for identifying patients for treatment with deferasirox therapy. Dose verification 3 months For chronic transfusional iron overload due to blood transfusion :serum ferritin consistently greater than 1000 mcg/l. For NON-transfusion dependent thalassemia syndrome and chronic iron overload a LIC (liver iron concentration) of at least 5 mg Fe/g dry weight and a serum ferritin greater than 300 mcg/l on at least 2 measurements 1 month apart. For patients continuation: Current LIC is greater than 3 mg per gram of dry weight or Exjade will be withheld until the LIC reaches above 5 mg per gram of dry weight 40
41 FARYDAK Farydak Other Diagnosis, other therapies tried and/or failed Prescription must be written by an oncologist 3 months initial, 6 months for continuation 41
42 FASENRA Fasenra Other Allergen test, baseline FEV1, FEV1 following bronchodilator, asthma medical history (including medications, emergency department visits, and hospitalizations), baseline eosinophil count Must be prescribed by a Pulmonologist or Immunologist or Allergist Initiation: 3 months, continuation 1 year Patient must be diagnosed with severe asthma, currently receiving inhaled and/or oral corticosteroid treatment, AND have a baseline eosinophil count of 150 cells/mcl or greater within previous 12 months. 42
43 FERRIPROX Ferriprox oral tablet Other Diagnosis, length of therapy, serum ferritin concentrations and dose/weight verification, & CBC 3 months Must have a contraindication to, an inadequate response, or has been intolerant to, or experienced clinically significant adverse effects to Exjade, such as evidence of cardiac iron overload or iron-induced cardiac dysfunction with Exjade. For continuation patient must have a 20% or greater reduction in serum ferritin with an adequate dose and duration of therapy. 43
44 FULYZAQ Mytesi Other Use when infectious diarrhea has not been ruled out Diagnosis, use of antiretroviral therapy 3 months Infectious diarrhea needs to be ruled out prior to initiating treatment. Patient must have a history of using at least two prior treatments for diarrhea, including bismuth subsalicylate, kaolin, loperamide, or diphenoxylate/atropine. 44
45 FYCOMPA Fycompa oral suspension Fycompa oral tablet Other Diagnosis, other therapies tried, response to prior therapy Prescription must be prescribed by neurologist 12 months Monitor at initiation and after dose increases for serious psychiatric and/or behavioral reactions. 45
46 GALAFOLD Galafold Other Not covered in combination with Fabrazyme Confirmed diagnosis of Fabry disease and baseline renal function assessment Prescription must be written by a specialist in genetic disorders, or nephrologist 6 months for initiation, 1 year for continuation 46
47 GATTEX Gattex 30-Vial Other Therapy should be discontinued in cases of intestinal malignancy. Diagnosis, other therapies tried and/or failed. Prescription must be written by a gastroenterologist 3 months for initiation, 6 months for continuation A colonoscopy of the entire colon with removal of polyps must be done before initiating therapy, medical records documenting this procedure must be submitted. 47
48 GAUCHER'S DISEASE TREATMENT Cerdelga Zavesca miglustat Other NOT APPROVED FOR TYPE II OR TYPE III GAUCHER'S DISEASE DIAGNOSIS, WEIGHT. FOR MIGLUSTAT: RATIONALE AS TO WHY ERT IS NOT APPROPRIATE PRESCRIPTION MUST BE WRITTEN BY GENETICIST, HEMOTOLOGIST, OR METABOLIC SPECIALIST 1 YEAR USE OF MIGLUSTAT IS RESERVED FOR THOSE WHOM ENZYME REPLACEMENT THERAPY IS NOT AN OPTION 48
49 GILOTRIF Gilotrif Other Diagnosis, previous therapies tried and/or failed Prescription must be written by oncologist 12 months 49
50 GLEEVEC imatinib Other DIAGNOSIS, PRIOR THERAPIES, AND TREATMENT RESPONSE PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST 3 MONTHS INITIAL, 6 MONTHS CONTINUATION GENETIC, HEMATOLOGIC, AND CYTOGENIC TESTS ARE REQUIRED BASED ON THE SPECIFIC INDICATION TO ASSESS APPROPRIATE USE AND ADEQUATE RESPONSE TO THERAPY 50
51 GRALISE Gralise Gralise 30-Day Starter Pack Covered Uses Other All medically accepted indications not otherwise excluded under Part D Diagnosis, previous treatments including dosage, outcome of previous treatment 1 year Must have a documented intolerance, contraindication to, or failure of gabapentin titrated to maximum tolerated dosage or rationale as to why gabapentin cannot be used. 51
52 GROWTH HORMONE Norditropin FlexPro Nutropin AQ Nuspin Other PRESENCE OF CONTRAINDICATIONS TO THERAPY DIAGNOSIS, HEIGHT AND WEIGHT, HISTORY OF GROWTH MEASUREMENT. REPLACEMENT THERAPY IN PATIENTS WITH GROWTH HORMONE DEFICIENCY WITH DIAGNOSIS CONFIRMED BY APPROPRIATE GROWTH HORMONE STIMULATION TESTING PRESCRIPTION MUST BE WRITTEN BY ENDOCRINOLOGIST OR NEPHROLOGIST 3 MONTHS FOR INITIATION, 1 YEAR FOR CONTINUATION 52
53 HEPATITIS B Baraclude oral solution entecavir Other TREATMENT CONSIDERATION IS BASED ON HBEAG, HBV DNA QUANTITY, AND ALT LEVEL PRESCRIPTION MUST BE WRITTEN BY A GASTROENTEROLOGIST, HEPATOLOGIST, OR INFECTIOUS DISEASE SPECIALIST 1 YEAR 53
54 HEPATITIS C TREATMENT Harvoni Ribasphere oral capsule ledipasvir-sofosbuvir ribavirin oral capsule Mavyret ribavirin oral tablet 200 mg Rebetol oral solution Zepatier Other PATIENT WEIGHT, GENOTYPE, HCV-RNA, LEVEL OF FIBROSIS, TREATMENT HISTORY PRESCRIPTION MUST BE WRITTEN BY GASTROENTEROLOGIST, HEPATOLOGIST, OR INFECTIOUS DISEASE SPECIALIST 8-24 WEEKS. TREATMENT WILL BE APPROVED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE. FOR COVERAGE OF HARVONI OR ZEPATIER: MUST HAVE FAILURE, INTOLERANCE, OR CONTRAINDICATION TO MAVYRET. 54
55 HEREDITARY ANGIOEDEMA Cinryze Haegarda Firazyr Takhzyro Other Diagnosis, including the results immunologic laboratory testing that show low C4 and functional C1- inhibitor levels Prescription must be written by Allergist or Immunologist 3 months initially, 12 months for continuation Prophylactic treatment with Cinryze is limited to patients who experience one or more severe attacks per month, on average. 55
56 HETLIOZ Hetlioz Other Diagnosis, other therapies tried and/or failed 3 months initial, 1 year continuation 56
57 HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA Juxtapid Kynamro Other Diagnosis, prior therapy used, results of prior therapy 3 months for initiation, 6 months for continuation Patient must have a diagnosis of homozygous familial hypercholesterolemia. Liver function tests required at baseline and at least monthly during the first year of treatment. 57
58 IBRANCE (S) Ibrance Other Prescription must be written by an oncologist 3 months initial, 6 months for continuation Must have a failure, contraindication, or intolerance to Kisqali 58
59 ICLUSIG Iclusig Other Diagnosis, prior therapy used, result of prior therapy. Prescription must be written by an oncologist or hematologist 3 months for initiation, 6 months for continuation Liver function monitoring required at baseline and 3 months after initiation 59
60 IDHIFA Idhifa Other Diagnosis, previous treatments, and outcome. Prescribed by or in consultation with a hematologist/oncologist. 12 months 60
61 IMBRUVICA Imbruvica oral capsule 140 mg, 70 mg Imbruvica oral tablet Other DIAGNOSIS, PRIOR TREATMENTS, RESPONSE TO THERAPY Prescription must be prescribed by oncologist, hematologist, or transplant specialist 12 months 61
62 INCRELEX Increlex Other DIAGNOSIS, HEIGHT AND WEIGHT MEASUREMENTS, GH LEVEL, IGF-1 LEVEL PRESCRIPTION MUST BE WRITTEN BY ENDOCRINOLOGIST 3 MONTHS INITIAL, 1 YEAR CONTINUATION 62
63 INHALED TOBRAMYCIN Tobi Podhaler inhalation capsule, w/inhalation device Other Diagnosis, therapies tried, and outcome Prescribed by Infectious disease specialist or pulmonologist 1 year 63
64 INLYTA Inlyta oral tablet 1 mg, 5 mg Other DIAGNOSIS, PRIOR TREATMENTS, RESPONSE TO THERAPY 18 YEARS OF AGE AND OLDER PRESCRIPTION MUST BE WRITTEN BY A ONCOLOGIST 3 MONTHS FOR INITIATION, 6 MONTHS FOR CONTINUATION 64
65 INTERFERON ALPHA Intron A injection Pegintron subcutaneous pen injector Pegasys Pegasys ProClick subcutaneous pen Pegintron Kit injector 180 mcg/0.5 ml Other FOR HEPATITIS C: PATIENT WEIGHT, GENOTYPE, HCV-RNA QUANTITY AND DATE OF TEST, PRESENCE OF DIRRHOSIS (Y/N), TREATMENT HISTORY, HISTORY OF ANEMIA OR DEPRESSION. HEPATITIS B: HBEAG STATUS, HBV DNA QUANTITY, AND ALT LEVEL. OTHERS: DIAGNOSIS, OTHER THERAPIES TRIED AND FAILED, RESPONSE TO TREATMENT 1 YEAR FOR INDICATIONS OTHER THAN HEPATITIS C. HEPC APPROVALS FROM WEEKS BASED ON DRUG REGIME 65
66 INTUNIV guanfacine oral tablet extended release 24 hr Other DIAGNOSIS AND THERAPIES TRIED AND FAILED. 1 year 66
67 IRESSA Iressa Other Diagnosis, prior therapy used, response to prior therapy PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST 3 MONTHS INITIAL, 1 YEAR CONTINUATION GEFITINIB IS COVERED AS MONOTHERAPY 67
68 IVIG Bivigam Carimune NF Nanofiltered intravenous recon soln 6 gram Flebogamma DIF intravenous solution 5, 10 % Gammagard Liquid Gammagard S-D (IgA < 1 mcg/ml) Gammaked injection solution 1 gram/10 ml (10 %) Hizentra Hyqvia Gammaplex Gammaplex (with sorbitol) Gamunex-C injection solution 1 gram/10 ml (10 %) Octagam Privigen Cuvitru Other DIAGNOSIS, OTHER THERAPIES TRIED AND FAILED, RESPONSE TO TREATMENT 3 MONTHS FOR INITIATION, 6 MONTHS FOR CONTINUATION DIAGNOSIS AND ADMINISTRATION INFORMATION WILL BE REVIEWED TO DETERMINE IF COVERAGE IS AVAILABLE AS A MEDICARE PART B OR PART D BENEFIT 68
69 JAKAFI Jakafi Other DIAGNOSIS, OTHER TREATMENTS TRIED AND FAILED, CBC AT BASELINE AND PERIODICALLY AFTER INITIATION, HISTORY OF RBC TRANSFUSIONS 18 YEARS AND OLDER PRESCRIBER MUST BE A HEMATOLOGIST OR ONCOLOGIST 3 MONTHS FOR INITATION, 6 MONTHS FOR CONTINUATION PATIENT MUST HAVE PALPABLE SPLENOMEGALY AT BASELINE AND SHOW A REDUCTION IN SPLEEN VOLUME AND SYMPTOM IMPROVEMENT FOR CONTINUATION OF THERAPY 69
70 JYNARQUE Jynarque Other History of signs or symptoms of significant liver impairment or injury Documented diagnosis of polycystic kidney disease, ultrasound results Prescribed by endocrinology or nephrology 6 months initial, 1 year continuation 70
71 KALYDECO Kalydeco Other Diagnosis and the presence of one or more specific gene mutations that the drug is FDA approved to treat. 3 months initially, 12 months for continuation 71
72 KEVZARA Kevzara subcutaneous syringe Other Diagnosis, other therapies tried and outcome, negative TB test, baseline LFTs and for continuation of therapy, CBC, and serum lipid profile at baseline and for continuation of therapy. Must be prescribed by a Rheumatologist Initiation: 3 months, continuation 1 year Must have a documented failure with two of the following TNF drugs: Humira, Enbrel, or Infliximab 72
73 KINERET Kineret Other Diagnosis, other therapies tried and/or failed Prescription must be written by rheumatologist or pediatrician 3 months initially, 6 months for continuation for gout is limited to patients who have tried a maximum tolerated dose of a xanthine oxidase inhibitor (i.e.: allopurinol) 73
74 KISQALI Kisqali Kisqali Femara Co-Pack Other Diagnosis, other therapies previously tried, and the outcome. Prescribed by or in consultation with an oncologist 3 months initial and 6 months for continuation of therapy 74
75 KORLYM Korlym Other Diagnosis, other therapies tried and outcome, HbA1c Prescribed by endocrinologist 1 year Must have trial of ketoconazole or metyrapone therapy or have intolerance or contraindication to these medications. Must have failed surgery or not be a candidate for surgery. For continuation of therapy patient must show an improvement in HbA1c. 75
76 KUVAN Kuvan oral powder in packet 100 mg Kuvan oral tablet,soluble Other DIAGNOSIS AND BASELINE AND FOLLOW UP PHENYLALANINE LEVELS. FOR CONTINUATION, MUST SHOW A 30% REDUCTION IN PHE LEVELS FROM BASELINE 2 MONTHS FOR INITIATION, 1 YEAR FOR CONTINUATION 76
77 LENVIMA Lenvima Other Prescription must be written by an oncologist 1 year 77
78 LEUKINE Leukine injection recon soln DIAGNOSIS ACUTE MYELOID LEUKEMIA (AML): GREATER OR EQUAL TO 55 YEARS OLD. Other 3 MONTHS AT A TIME 78
79 LIBTAYO Libtayo Other Diagnosis, other therapies tried and/or failed, and response to prior therapy Prescription must be written by or in consultation with an oncologist or hematologist 1 YEAR 79
80 LIDOCAINE TRANSDERMAL lidocaine topical adhesive patch,medicated lidocaine topical ointment Other DIAGNOSIS AND OTHER THERAPIES TRIED AND FAILED 1 YEAR FOR LIDOCAINE PATCH: MUST HAVE A USED A PREVIOUS TRIAL OF GABAPENTIN FOR THE TREATMENT OF POST- HERPETIC NEURALGIA OR DIABETIC NEUROPATHY 80
81 LINZESS Linzess Other Diagnosis and previous treatments 1 year Must have a failure, contraindication or intolerance to Amitza 81
82 LOKELMA Lokelma Other Diagnosis of hyperkalemia, confirmed with laboratory test within the past month. 6 months for initiation, 1 year for continuation For initiation, must have a failure, contraindication, or intolerance to sodium polystyrene sulfonate. For continuation, must show response to therapy as demonstrated by normal potassium levels and patient remains at high risk for recurrence of hyperkalemia. 82
83 LONSURF Lonsurf Other Diagnosis, other therapies tried and/or failed, and treatment response Prescription must be written by an oncologist 1 year 83
84 LORBRENA Lorbrena Other Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment. Prescription must be written by an oncologist 1 year 84
85 LYNPARZA Lynparza oral tablet Other DIAGNOSIS, PRIOR THERAPIES, GENETIC TESTING PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST 3 months initiation, 6 months continuation Patients must have failed greater than equal to 3 prior courses of chemotherapy and have BRCA-positive or suspected BRCA-positive advanced ovarian cancer 85
86 MEDICALLY ACCEPTED USE gabapentin oral capsule megestrol oral tablet gabapentin oral solution 250 mg/5 ml topiramate oral capsule, sprinkle gabapentin oral tablet 600 mg, 800 mg topiramate oral tablet Lyrica zonisamide megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml Other Diagnosis 1 year 86
87 MEKINIST Mekinist oral tablet 0.5 mg, 2 mg Other Wild-type BRAF melanoma Diagnosis, prior therapy used, result of prior therapy. Documentation of BRAF mutation, as detected using an FDA-approved test. Prescription must be written by an oncologist 1 year 87
88 MEKTOVI Mektovi Other Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment. Prescription must be written by an oncologist 3 months for initiation, 1 year for continuation Must be used in combination with encorafenib. 88
89 METHADONE methadone oral solution methadone oral tablet Other Diagnosis and any prior treatments. 6 months Monitor for possible misuse, including early refill history and multiple treating physicians 89
90 METHAMPHETAMINE methamphetamine Other Diagnosis, other therapies previously tried and failed, and response to treatment 1 year For the treatment of attention deficit disorder patient must have a trial of both methylphenidate and amphetamine/dextroamphetamine or rationale as to why these treatments are not suitable. 90
91 MIRVASO Mirvaso topical gel with pump Other Documentation of diagnosis and other treatments tried and outcome. 1 year For the treatment of acne rosacea: doxycycline (oral) and topical metronidazole. 91
92 MOVANTIK Movantik Covered Uses Other All medically accepted indications not otherwise excluded from Part D Will not be approved for cancer related pain Documented diagnosis of opiate induced constipation (non-cancer pain) 1 year Patient must have a trial of or contraindication to at least two different classes of laxative agents including bulk, osmotic, or stimulant laxatives. 92
93 MULTIPLE SCLEROSIS Aubagio Avonex (with albumin) Avonex intramuscular pen injector kit Avonex intramuscular syringe kit Betaseron subcutaneous kit Extavia subcutaneous kit Gilenya oral capsule 0.5 mg glatiramer Glatopa Rebif (with albumin) Rebif Rebidose Rebif Titration Pack Tecfidera Covered Uses Other All medically accepted indications not otherwise excluded under Part D Diagnosis, EDSS score, relapse history, and physical or cognitive disability neurologist 1 year For Aubagio, Extavia, Tecfidera, and Rebif- must have a failure of one of the following: Avonex, Betaseron, Glatopa, Glatiramer, or Gilenya 93
94 MYALEPT Myalept Other Diagnosis, prior therapy used, result of prior therapy 3 months for initiation, 1 year for continuation 94
95 NATPARA Natpara Other DIAGNOSIS, BASELINE SERUM CALCIUM AND 25- HYDROXYVITAMIN D LEVELS MUST BE PRESCRIBED BY AN ENDOCRINOLOGIST 1 year 95
96 NERLYNX Nerlynx Other Diagnosis, previous treatments, and outcome. Prescribed by or in consultation with an oncologist 12 months Approve for continuation of prior therapy if treatment duration of Nerlynx has not exceeded a total of 12 months 96
97 NEUPRO Neupro Other Diagnosis, other therapies tried and/or failed, frequency of symptoms 1 year Patient must have a trial of or contraindication to two of the following therapies prior to coverage of Neupro: pramipexole, ropinirole, or carbidopa/levodopa. 97
98 NEXAVAR Nexavar Other DIAGNOSIS, PRIOR THERAPIES, AND TREATMENT RESPONSE PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST 3 MONTHS INITIAL, 1 YEAR CONTINUATION 98
99 NINLARO Ninlaro Other Diagnosis, other therapies tried and/or failed, and treatment response. Used in combination with Revlimid (lenalidomide) and dexamethasone. Prescription must be written by an oncologist or hematologist 3 months for initial 6 months for continuation Must have an intolerance or contraindication to Velcade 99
100 NOXAFIL Noxafil oral Other Diagnosis, therapies tried, and outcome Prescribed Infectious disease specialist 6 months For the treatment of aspergillosis patient must have failure of, intolerance or contraindication to vorconizole OR rationale as to why vorconizole is not suitable. 100
101 NUCALA Nucala Other For patients with asthma: allergen test, baseline FEV1, FEV1 following bronchodilator, asthma medical history (including medications, emergency department visits, and hospitalizations), baseline eosinophil count. For patients with eosinophilic granulomatosis with polyangiitis: documentation of diagnosis, prior therapies, and the outcome. Pulmonology, immunologist, or allergist 3 months for initial, 1 year for continuation For patients with asthma: must be currently receiving inhaled and/or oral corticosteroid treatment, AND have a baseline eosinophil count of 300 cells/mcl or greater within previous 12 months or 150 cell/mcl within previous 6 weeks. 101
102 NUEDEXTA Nuedexta Other Diagnosis Prescription must be written by a neurologist or psychiatrist. 1 year 102
103 NUPLAZID Nuplazid Other Parkinson's disease psychosis: Diagnosis of Parkinson's disease. Patient has at least one of the following: hallucinations or delusions. 1 year 103
104 OCALIVA Ocaliva Other Diagnosis, other therapies tried and failed, and response to therapy, baseline alkaline phosphatase (ALP) level for initiation, and ALP levels after first 3 months of therapy and then yearly for continuation of therapy. 3 months for initial and 1 year for continuation ALP levels are still elevated with at least 12 consecutive months of Actigall/Ursodiol use (at maximum dose of mg/kg/day) unless intolerant to Acitgal/Ursodiol. Must be used in combination with Actigal/Ursodiol. If intolerant to Actigal/Ursodiol can be used as monotherapy. Must show improvement of ALP levels for continuation. 104
105 OCTREOTIDE octreotide acetate injection solution Other Diagnosis, other therapies tried and failed 1 year 105
106 ODOMZO Odomzo Other Patient has recurring disease following surgery or radiation OR patient is not a candidate for surgery or radiation therapy Prescription must be written by an oncologist or dermatologist 1 year 106
107 OPSUMIT Opsumit Other Confirmation of diagnosis, documentation of response to any prior therapies Prescription must be written by pulmonologist or cardiologist 3 months initial, 1 year continuation Patient must have a history of taking bosentan (Tracleer), or a contraindication to bosentan that does not apply to Opsumit. 107
108 ORENCIA Orencia subcutaneous syringe 125 mg/ml Other DIAGNOSIS AND OTHER THERAPIES TRIED AND FAILED, NEGATIVE TB TEST PRESCRIPTION MUST BE WRITTEN BY A RHEUMATOLOGIST 3 MONTHS INITIAL, 1 YEAR CONTINUATION PATIENT MUST HAVE A DOCUMENTED FAILURE WITH AT LEAST ONE DMARD AND EITHER HUMIRA OR ENBREL 108
109 ORFADIN Orfadin Other DIAGNOSIS AND WEIGHT PRESCRIPTION MUST BE WRITTEN BY AN ENDOCRINOLOGIST, GASTROENTEROLOGIST, HEMATOLOGIST, METABOLIC SPECIALIST, OR NEPHROLOGIST 3 MONTHS INITIAL, 1 YEAR CONTINUATION CLOSE MONITORING OF DISEASE MARKERS (ERYTHROCYTE PBG-SYNTHASE ACTIVITY, URINE 5-ALA, SUCCINYLACETONE) DURING THE FIRST 3 MONTHS OF TREATMENT TO ENSURE NORMALIZATION 109
110 ORKAMBI Orkambi oral granules in packet Orkambi oral tablet Other Patient has a diagnosis of cystic fibrosis (CF) AND Patient is homozygous for the F508del mutation in the CF transmembrane conductance regulator (CFTR) gene AND The presence of the mutation was documented by an FDA-cleared cystic fibrosis mutation test. 6 months initial, 12 months for continuation For renewal, Patient is benefiting from treatment (i.e., improvement in lung function [forced expiratory volume in one second [FEV1], decreased number of pulmonary exacerbations) 110
111 ORLISSA Orilissa Other Diagnosis, prior therapies, and result of prior therapy. 1 year Must have a failure, contraindication, or intolerance to a continuous hormonal contraceptive AND progestin therapy (e.g. medroxyprogesterone, norethindrone). 111
112 OTEZLA Otezla Otezla Starter oral tablets,dose pack 10 mg (4)-20 mg (4)-30 mg (47) Other Diagnosis, prior therapy used, result of prior therapy Must be prescribed by a Rheumatologist or Dermatologist 3 months for initiation, 1 year for continuation Patient must have failure of, intolerance or contraindication to at least one formulary TNF inhibitor (including but not limited to Humira, Enbrel, Cimzia, or Infliximab) 112
113 OXERVATE Oxervate Other Diagnosis, prior therapies, and result of prior therapy. Prescription must be written by an ophthalmologist 8 weeks 113
114 OXYCONTIN oxycodone oral tablet,oral only,ext.rel.12 hr Other DIAGNOSIS, OTHER THERAPIES TRIED AND FAILED, RESPONSE TO TREATMENT, OTHER OPIATES CURRENTLY BEING USED 6 MONTHS MONITOR FOR POTENIAL MISUSE INCLUDING EARLY REFILL HISTORY, MULTIPLE CONCURRENT LONG ACTING OPIATES OVER 3 MONTH PERIOD, AND MULTIPLE TREATING PHYSICIANS 114
115 PALYNZIQ Palynziq Other Diagnosis, prior treatments, and outcome. Baseline and follow up phenylalanine (Phe) concentrations. 3 months for initial, 1 year for continuation Must have phenylalanine (Phe) concentrations greater than 600 micromol/l on existing management, and a failure, contraindication, or intolerance to Kuvan. 115
116 PANRETIN Panretin Other NOT INDICATED WHEN SYSTEMIC ANTI-KS THERAPY IS REQUIRED. 6 MONTHS 116
117 PCSK9 INHIBITORS Praluent Pen Repatha SureClick Repatha Covered Uses Other All medically accepted indications not otherwise excluded under Part D Submission of clinical and laboratory evidence documenting heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, or clinical atherosclerotic cardiovascular disease- ASCVD (defined as history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin). Baseline LDL-C within 30 days prior to request, and documentation of other therapies tried and the outcome. Repeat LDL- C within 60 days of each prior authorization request. Prescribed by a cardiologist, endocrinologist, or lipid specialist Initial 6 months. Renewal 1 year. Member must have tried and failed at least 2 different statins including fluvastatin. Praluent/Repatha must be received with maximally tolerated statin therapy unless statin therapy cannot be used. LDL-C with in 30 days of request greater than or equal to 100mg/dL with ASCVD or LDL-C greater than or equal to 130mg/dL without ASCVD. 117
118 POMALYST Pomalyst Other Diagnosis, prior therapy used, result of prior therapy. Prescription must be written by an oncologist or hematologist 1 year 118
119 PROLIA Prolia Other PRESENCE OF ABSOLUTE CONTRAINDICATION TO THERAPY DIAGNOSIS AND OTHER THERAPIES TRIED AND FAILED 18 YEARS AND OLDER 1 YEAR PATIENT MUST HAVE A DOCUMENTED FAILURE OR CONTRAINDICATION TO A BISPHOSPHONATE AGENT. 119
120 PROMACTA Promacta Other Diagnosis, other therapies tried and/or failed, and platelet count INITIAL FILL FOR 6 MONTHS, 1 YEAR THEREAFTER 120
121 PROVIGIL modafinil Other DIAGNOSIS AND OTHER THERAPIES TRIED AND FAILED. 1 YEAR 121
122 PULMONARY FIBROSIS Esbriet Ofev Other liver function prescriber must be a pulmonologist. 1 year 122
123 PULMONARY HYPERTENSION Adcirca Ventavis Letairis sildenafil (Pulmonary Arterial Tyvaso Hypertension) oral Tracleer CONFIRMATION OF DIAGNOSIS OF PAH (WHO GROUP 1 OR HIGHER), DOCUMENATION OF RESPONSE TO THERAPY PRESCRIPTION MUST BE WRITTEN BY PULMONOLOGIST OR CARDIOLOGIST 1 YEAR Other Ventavis will also be reviewed for coverage under part B versus part D. Prior to coverage of sildenafil, the plan will determine whether the diagnosis meets part D requirements for approval 123
124 PURIXAN Purixan Other DIAGNOSIS, PRIOR TREATMENTS, RESPONSE TO THERAPY prescriber must be a oncologist or hematologist 1 year 124
125 RELISTOR Relistor oral Relistor subcutaneous syringe Relistor subcutaneous solution Other Diagnosis and prior therapies tried and failed 3 months for initiation, 1 year for continuation For the treatment of opioid-induced constipation associated with chronic noncancerous pain: prior trial of or contraindication to at least one class of laxative agents (including bulk, osmotic, or stimulant laxatives) AND Amitiza. For all other conditions: a trial of or contraindication to at least two different classes of laxative agents (including bulk, osmotic, or stimulant laxatives) 125
126 REVLIMID Revlimid Other DIAGNOSIS, OTHER THERAPIES TRIED AND FAILED, RESPONSE TO TREATMENT 18 YEARS AND OLDER PRESCRIPTION MUST BE WRITTEN BY AN ONCOLOGIST 1 year 126
127 RUBRACA Rubraca Other Ovarian cancer: Diagnosis of advanced ovarian cancer. Presence of deleterious BRCA mutation as detected by an FDA-approved diagnostic test (e.g., Foundation Focus CDxBRCA Assay). History of failure, contraindication, or intolerance to two or more chemotherapies (e.g., cisplatin, carboplatin). Prescribed by or in consultation with an oncologist 12 months 127
128 RYDAPT Rydapt Other Acute Myeloid Leukemia (AML): Newly diagnosed acute myeloid leukemia (AML), FMS-like tyrosine kinase 3 (FLT3) mutation-positive as detected by a U.S. Food and Drug Administration (FDA)-approved test, used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Aggressive Systemic Mastocytosis (ASM), Systemic Mastocytosis with Associated Hematological Neoplasm (SM- AHN), Mast Cell Leukemia (MCL): Diagnosis of one of the following: aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). All indications: Prescribed by or in consultation with a hematologist or oncologist. 1 year Approve for continuation of prior therapy 128
129 SAMSCA Samsca Other Diagnosis, patient has a serum sodium less than 125 meq/l at baseline, OR member has less marked hyponatremia (serum sodium less than 135 meq/l at baseline) AND is symptomatic (e.g. nausea, vomiting, headache, lethargy, confusion, and baseline LFTs) Prescribed by endocrinology or nephrology 1 month Patient must have documented failure of two other therapies (e.g. fluid restriction, furosemide, demeclocycline). 129
130 SAVELLA Savella oral tablet Savella oral tablets,dose pack Other DIAGNOSIS OF FIBROMYALGIA, RESPONSE TO THERAPY 1 YEAR 130
131 SIGNIFOR Signifor Other Diagnosis, other therapies tried and failed, result of prior pituitary surgery (if performed). If not surgery was performed, provide the reason why surgery is not an option. Prescription must be written by an endocrinologist 3 months for imitation, 6 months for continuation 131
132 SIRTURO Sirturo Other Diagnosis, other therapies tried and/or failed. ECG and liver function tests are required at baseline and at intervals as specified in the FDA prescribing information to monitor for potentially severe adverse events. Prescription must be written by a infectious disease specialist 24 weeks Drug therapy must be directly observed. Use of Sirturo is reserved for MDR-TB where other treatment options cannot be used for safety or efficacy reasons. 132
133 SORIATANE acitretin Other Female patients who are pregnant or planning to become pregnant within the next three years Diagnosis, other therapies tried and/or failed Prescription must be written by dermatologist, oncologist, or transplant physician 3 months for initiation, 6 months for continuation For the treatment of psoriasis, patient must have a trial of or contraindication to topical therapy and methotrexate. For the prevention of skin cancer in solid organ transplant patients, Soriatane will be covered for patients who develop multiple (greater than 5) squamous cell carcinoma (SCC) lesions per year, aggressive SCC, or accelerated development of SCC 133
134 SPRITAM Spritam Other Diagnosis, therapies tried, and outcome Prescribed by Neurologist 1 year Rationale as to why generic levetiracetam is not suitable. 134
135 SPRYCEL Sprycel Other PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST 1 year Must have a failure, intolerance or contraindication to imatinib. 135
136 STELARA Stelara subcutaneous Other Diagnosis, prior therapies, and result of prior therapy. TB test results Prescribed by gastroenterologist or rheumatologist 1 year For psoriasis and psoriatic arthritis: Patient must have failure of, intolerance, or contraindication to inflixmab and Otezla. For Crohn's disease: Patient must have a failure of, intolerance, or contraindication to infliximab and Humira. 136
137 STIVARGA Stivarga Other Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to regorafenib. LFT lab test results are needed for continuation treatment. Prescription must be written by an oncologist 1 year 137
138 SUPREP Suprep Bowel Prep Kit Other Diagnosis, other therapies tried and outcome 1 year Must have a failure, contraindication, or intolerance to at least one generic bowel prep ie. Trilyte 138
139 SUTENT Sutent DIAGNOSIS, PRIOR THERAPIES, AND TREATMENT RESPONSE. DOCUMENATION OF FAILURE OF IMATINIB FOR PATIENTS WITH GIST. DOCUMENTATION OF FAILURE OF VOTRIENT FOR PATIENTS WITH RENAL CELL CARCINOMA. IF NO PREVIOUS FAILURE, RATIONALE AS TO WHY PREFERRED AGENT CANNOT BE USED PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST 3 MONTHS INITIAL, 1 YEAR CONTINUATION Other GIST PATIENTS REQUIRE A FOLLOW-UP CT SCAN BETWEEN 8 AND 12 WEEKS. 139
140 SYLATRON Sylatron Other HISTORY OF HEPATITIS OR HEPATIC DECOMPENSATION DIAGNOSIS OF MALIGNANT MELANOMA WITH EVIDENCE OF NODAL INVOLVEMENT 18 YEARS AND OLDER PRESCRIBER MUST BE ONCOLOGIST OR DERMATOLOGIST 6 MONTHS MONITOR FOR NEUROPSYCHIATRIC DISORDERS, TOXICITY, AND NEW OR WORSENING RETINOPATHY 140
141 SYMDEKO Symdeko Other Diagnosis of CF AND homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. FEV1 at baseline and continuation, baseline LFT and continuation, review for drug interactions CYP3A inducers 12 and older Must be prescribed by a pulmonologist or doctor specializing in cystic fibrosis 6 months initial, 1 year continuation For renewal, Patient is benefiting from treatment (i.e., improvement in lung function [forced expiratory volume in one second (FEV1)], decreased number of pulmonary exacerbations) 141
142 SYMLIN SymlinPen 120 SymlinPen 60 Other GASTROPARESIS OR USE OF DRUGS TO STIMULATE GASTROINTESTINAL MOTILITY HBA1C AND CURRENT DIABETES MEDICATIONS 1 YEAR 142
143 SYMPAZAN Sympazan oral film 10 mg, 20 mg, 5 mg Other Diagnosis, prior therapy used, result of prior therapy. 1 year Must have failure, intolerance, or contraindication to generic clobazam 143
144 SYNRIBO Synribo Other Diagnosis, prior therapy used, result of prior therapy. Prescription must be written by an oncologist or hematologist 3 months for initiation, 6 months for continuation 144
145 TAFINLAR Tafinlar Other Wild-type BRAF melanoma Diagnosis, prior therapy used, result of prior therapy. Documentation of BRAF mutation, as detected using an FDA-approved test. Prescription must be written by an oncologist 1 year 145
146 TAGRISSO Tagrisso Other Diagnosis, other therapies tried and/or failed, and treatment response. For NCSLC: Tumors are positive for epidermal growth factor receptor (EGFR) T790M mutation. Prescribed by an oncologist. 1 year 146
147 TALZENNA Talzenna Other Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment. Prescription must be written by an oncologist 1 year 147
148 TARCEVA Tarceva Other DIAGNOSIS, PRIOR THERAPIES, AND TREATMENT RESPONSE PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST 1 year 148
149 TASIGNA Tasigna oral capsule 150 mg, 200 mg, 50 mg Other DIAGNOSIS, OTHER THERAPIES TRIED AND FAILED, RESPONSE TO TREATMENT, POTENTIAL DRUG INTERACTIONS PRESCRIPTION MUST BE WRITTEN BY AN ONCOLOGIST 1 year Must have a failure, intolerance or contraindication to imatinib and Sprycel. 149
150 TAVALISSE Tavalisse Other Diagnosis, other therapies tried, outcome, and platelet count less than 50,000/microL for at least 3 months Must be prescribed by a hematologist or oncologist 3 months Patient must have a failure, contraindication, or intolerance to at least two of the following therapies: corticosteroids, IVIG, Rituxan, or Promacta. For continuation of therapy the platelet counts must be to a level sufficient to avoid clinically important bleeding. 150
Diagnosis of severe congenital A1-PI deficiency who have clinically evident emphysema, weight, A1-PI phenotype, A1-PI baseline level
AAT DEFICIENCY Aralast NP intravenous recon soln 1,000 mg Glassia Prolastin-C intravenous recon soln Zemaira Other Diagnosis of severe congenital A1-PI deficiency who have clinically evident emphysema,
More informationCovered Uses All medically accepted indications not otherwise excluded from Part D.
AAT DEFICIENCY Aralast NP intravenous recon soln 1,000 mg Glassia Prolastin-C intravenous recon soln Zemaira PA Details Age Other Diagnosis of severe congenital A1-PI deficiency who have clinically evident
More informationacromegaly Drugs Covered Uses Exclusion Criteria Required Medical Information Age Restriction Prescriber Restriction Coverage Duration
acromegaly SIGNIFOR, SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 120 MG/0.5 ML, 60 MG/0.2 ML, 90 MG/0.3 ML, SOMAVERT SUBCUTANEOUS RECON SOLN 15 MG, 20 MG, 25 MG, 30 MG All medically accepted indications not
More informationAAT DEFICIENCY. Products Affected Aralast Np INJ 1000MG, 500MG Glassia Prolastin-c INJ 1000MG Zemaira
AAT DEFICIENCY Aralast Np INJ 1000MG, 500MG Glassia Prolastin-c INJ 1000MG Zemaira PA Details Other Diagnosis of severe congenital A1-PI deficiency who have clinically evident emphysema, weight, A1-PI
More informationAAT DEFICIENCY. Products Affected Aralast Np INJ 1000MG, 500MG Glassia. Prior Authorization Criteria Health Alliance Plan_2016_HAPFB Updated: 10/2016
Prior Authorization Health Alliance Plan_2016_HAPFB Updated: 10/2016 AAT DEFICIENCY Products Affected Aralast Np INJ 1000MG, 500MG Glassia Prolastin-c Zemaira Covered Uses All FDA-approved indications
More informationSpecialty Drugs. The following is a list of medications that are considered to be specialty drugs. Specialty drugs
Specialty Drugs The following is a list of medications that are considered to be specialty drugs. Specialty drugs include self-administered injectables, medications that are high cost, and/or medications
More information2018 BCN Advantage Prior Authorization Criteria Last updated: November, 2017
Abstral Actemra Adcirca Adempas Afinitor Afinitor- Disperz Alecensa Alunbrig Amitiza Amitriptyline Ampyra Anadrol-50 Androgel Androderm Aralast NP Aranesp Arcalyst Armodafinil Aubagio Avonex Bavencio Beleodaq
More informationSpecialty Drugs. The specialty drug list below is effective June 5, 2018 and is subject to change at any time.
Specialty Drugs The following is a list of medications that are considered specialty drugs. Specialty drugs include self-administered injectables, medications that are high cost, and/or medications that
More information2018 BCN Advantage Prior Authorization Criteria Last updated: April, 2018
Abstral Actemra Adcirca Adempas Aliqopa Afinitor Afinitor- Disperz Alecensa Alunbrig Amitiza Amitriptyline Ampyra Anadrol-50 Androgel Androderm Aralast NP Aranesp Arcalyst Armodafinil Aubagio Avonex Bavencio
More informationAetna Better Health. Specialty Drug Program
Aetna Better Health is managed through CVS Health Specialty Pharmacy. The Specialty pharmacies fill prescriptions and ship drugs for complex medical conditions, including multiple sclerosis, rheumatoid
More informationANDROID. Products Affected ANDROID. Prior Authorization Criteria HEALTH CHOICE EXCHANGE Effective Date: 12/01/2016
Prior Authorization HEALTH CHOICE EXCHANGE Effective Date: 12/01/2016 ANDROID ANDROID Supporting statement of diagnosis from the physician. Other 1 BLINCYTO BLINCYTO Known hypersensitivity to blinatumomab
More informationACITRETIN. Products Affected
ACITRETIN acitretin Other For prophylaxis of skin cancer in patients with previously treated skin cancers who have undergone an organ transplantation the request will be approved. For psoriasis: the patient
More informationPPHP 2017 Formulary 2017 Step Therapy Criteria
ARISTADA Aristada Prefilled Syringe 1064 MG/3.9ML Intramuscular Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular Aristada Prefilled Syringe 882
More informationACITRETIN. Products Affected
ACITRETIN acitretin Other For prophylaxis of skin cancer in patients with previously treated skin cancers who have undergone an organ transplantation the request will be approved. For psoriasis: the patient
More informationANTIDEPRESSANTS. Details. Step Therapy 2017 Last Updated: 5/23/2017
ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG FETZIMA CAPSULE
More informationPlan Year 2017 Prior Authorization (PA) Criteria
Plan Year 2017 Prior Authorization (PA) Criteria Prior Authorization: Commonwealth Care Alliance requires you (or your physician) to get prior authorization for certain drugs. This means that you will
More informationPlan Year 2019 Prior Authorization (PA) Criteria
Plan Year 2019 Prior Authorization (PA) Criteria Prior Authorization: Commonwealth Care Alliance requires you (or your physician) to get prior authorization for certain drugs. This means that you will
More informationANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018
ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL FETZIMA
More informationErythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS *
Erythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS * DESCRIPTION Erythropoietin is a glycoprotein produced in the kidneys responsible for the stimulation of red blood cell production. Epoetin
More informationLista de medicamentos especializados
Lista de medicamentos especializados Vigencia: 1o. de enero de 2016 A continuación se listan, en orden alfabético, los medicamentos de especialidad recetados más frecuentemente. Los medicamentos de especialidad
More informationADCIRCA. Products Affected Adcirca. Prior Authorization Criteria 2017 MMP Effective Date: 11/01/2017 Approval Date: 11/01/2017
Prior Authorization 2017 MMP Effective Date: 11/01/2017 Approval Date: 11/01/2017 ADCIRCA Products Affected Adcirca PA Details All FDA-approved indications not otherwise Other Patients taking nitrates
More informationPrior treatment with non-biologic Disease- Modifying Antirheumatic. Not to be used in combination with another biologic DMARD
Abatacept (Orencia) 1, 2, 7, 11, 13, 14, 18, 24, 31, 44, 48, 49, 51, 53, 55, 57 J0129 Alpha 1 - Proteinase inhibitor (Prolastin-C) 5, 6, 10, 12, 40 Medically Necessary (if all the following criteria apply):
More informationACNE AGENTS_NVT Chinese Community Health Plan Senior Select Program (HMO SNP)
ACNE AGENTS_NVT adapalene topical cream adapalene topical gel Avita tretinoin tretinoin microspheres topical gel Age Other 1 ADAGEN_NVT Adagen Age Other 2 ADCIRCA_NVT 2017 Adcirca Diagnosis confirmed by
More informationPlan Year 2018 Prior Authorization (PA) Criteria
Plan Year 2018 Prior Authorization (PA) Criteria Prior Authorization: Commonwealth Care Alliance requires you (or your physician) to get prior authorization for certain drugs. This means that you will
More informationGranite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18
Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18 Granite Alliance requires step therapy for certain drugs. This means prior to receiving a drug with a step therapy
More informationALPHA1-PROTEINASE INHIBITOR
Ally Rx D-SNP Current as of Nov. 1, 2018 ALPHA1-PROTEINASE INHIBITOR ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG GLASSIA PROLASTIN-C INTRAVENOUS RECON SOLN ZEMAIRA PA Documentation of diagnosis, lab results,
More informationUPMC for You Pharmacy and Therapeutics Committee Meeting April 8, 2013 meeting
UPMC for You Pharmacy and Therapeutics Committee Meeting April 8, 2013 meeting 1. Call to order: The meeting was called to order at 7:05 a.m. 2. Review of the minutes: The minutes of the January meeting
More informationARISTADA. Products Affected Step 2: ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.
ARISTADA ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.6ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 662 MG/2.4ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 882
More informationACNE AGENTS_NVT Chinese Community Health Plan Senior Select Program (HMO SNP)
ACNE AGENTS_NVT adapalene 0.3% gel pump adapalene topical cream adapalene topical gel avita tretinoin tretinoin microspheres topical gel Age Other 1 ADAGEN_NVT ADAGEN Age Other 2 ADCIRCA_NVT 2017 ADCIRCA
More informationHMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Epogen, Procrit (epoetin alfa, injection) Commercial HMO/PPO/CDHP
More informationACTEMRA. Products Affected ACTEMRA. Covered Uses All FDA-approved indications not otherwise excluded from Part D. N/A. Exclusion Criteria
ACTEMRA ACTEMRA New starts: Patient has a diagnosis of moderate to severe rheumatoid arthritis (IV or subcutaneous dosage form) and has had a failure, contraindication, or intolerance to two of the following:
More informationACROMEGALY THERAPY. Products Affected Somatuline Depot subcutaneous syringe 120 mg/0.5 ml, 60 mg/0.2 ml, 90 mg/0.3 ml
Prior Authorization Requirements Effective January 1, 2019 ACROMEGALY THERAPY Somatuline Depot subcutaneous syringe 120 mg/0.5 ml, 60 mg/0.2 ml, 90 mg/0.3 ml Somavert PA Age Other PATIENT PROGRESS NOTES,
More informationORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR
ABILIFY INJ ABILIFY MAINTENA PREFILLED SYRINGE 300 MG ABILIFY MAINTENA PREFILLED SYRINGE 400 MG ABILIFY MAINTENA SUSPENSION RECONSTITUTED ER 300 MG Claim will pay automatically for ABILIFY MAINTENA if
More informationCARE N CARE HEALTH PLAN
ARISTADA Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular Aristada Prefilled Syringe 882 MG/3.2ML Intramuscular Claim will pay automatically for
More informationACROMEGALY THERAPY. Products Affected Somatuline Depot subcutaneous syringe 120 mg/0.5 ml, 60 mg/0.2 ml, 90 mg/0.3 ml
Prior Authorization Requirements Effective January 1, 2019 ACROMEGALY THERAPY Somatuline Depot subcutaneous syringe 120 mg/0.5 ml, 60 mg/0.2 ml, 90 mg/0.3 ml Somavert PA Age PENDING CMS APPROVAL PATIENT
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
April 1, 2018 Bulletin #169 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Recommended as a full Formulary benefit: benztropine mesylate, tablet,
More informationBuckeye Health Plan (MMP) 2016 Prior Authorization Criteria
Buckeye Health Plan (MMP) 2016 Prior Authorization Instructions: 1. With this file, at the top, click Edit, then click Find. 2. In the Find box type the name of the medication you want to find. 3. Click
More informationList of Designated High-Cost Drugs
List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at
More informationSpecialty Drug List - Sorted by Therapeutic Class Developed for the Mississippi Division of Medicaid by Mercer
ANTI-INFECTIVE ABELCET 100 MG/20 ML VIAL 4/1/2017 ANTI-INFECTIVE AMBISOME 50 MG VIAL 4/1/2017 ANTI-INFECTIVE ANCOBON 250 MG CAPSULE 4/1/2017 ANTI-INFECTIVE ANCOBON 500 MG CAPSULE 4/1/2017 ANTI-INFECTIVE
More informationNexavar. Nexavar (sorafenib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.60 Section: Prescription Drugs Effective Date: July 1,2017 Subject: Nexavar Page: 1 of 5 Last Review
More informationAPPLICATION FORM CHRONIC MEDICINE BENEFIT 2019
APPLICATION FORM CHRONIC MEDICINE BENEFIT 2019 1. Medication for all chronic conditions that are covered may be registered telephonically on 0800 132 345 (doctors and pharmacists only). 2. Alternatively,
More informationCARE N CARE HEALTH PLAN
ARISTADA ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.6ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 662 MG/2.4ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 882
More informationSutent. Sutent (sunitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.95 Subject: Sutent Page: 1 of 5 Last Review Date: September 15, 2017 Sutent Description Sutent (sunitinib)
More informationORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationDRUGS REQUIRING PRIOR AUTHORIZATION
DRUGS REQUIRING PRIOR AUTHORIZATION Medication Abstral Actemra Acthar Gel Actiq* Adcirca Adderall Adderall XR Addyi Adempas Adipex* Adzenys XR-ODT Afinitor Afinitor Alecensa Alecensa Ampyra Androderm AndroGel
More informationSpecialty Overview by Prior Authorization Approval or Denial 2nd Quarter 2016
Specialty Overview by Prior Authorization Approval or 2nd Quarter 2016 3961 DERMATOLOGY Humira RHEUMATOID ARTHRITIS Approval Approved from 04/13/2016 thru 04/13/2018 3961 DERMATOLOGY Stelara PSORIASIS
More informationMedication Prior Authorization Form
Procrit, Aranesp and (Epoetin Alfa) Policy Number: 1043 Policy History Approve Date: 12/11/2015 Effective Date: 12/11/2015 Preauthorization All Plans Benefit plans vary in coverage and some plans may not
More information2019 Prior Authorizations (List of Prior Authorizations)
Prior Authorization Last Updated: March 20, 2019 Effective Date: April 1, 2019 2019 Prior Authorizations (List of Prior Authorizations) PLEASE READ CAREFULLY: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Multiple Sclerosis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationCENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY. Revision Summary or Description
CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY Coverage Guideline Policy & Procedure HIM.PA.32 Long acting stimulants (Adderall XR, Dexedrine, Metadate CD, Ritalin
More information2018 PRIOR AUTHORIZATION CRITERIA TABLE OF CONTENTS
2018 PRIOR AUTHORIZATION CRITERIA TABLE OF CONTENTS ADASUVE...25 ADCIRCA...12 ADEMPAS...14 AFINITOR... 140 AFINITOR DISPERZ... 140 ALECENSA... 140 ALUNBRIG... 140 amabelz tablet...90 AMITIZA...17 amitriptyline
More informationStep Therapy Requirements. Effective: 03/01/2015
Effective: 03/01/2015 Updated 02/2015 ANTI-INFLAMMATORY AGENTS - GI DIPENTUM PRIOR CLAIM FOR BALSALAZIDE OR APRISO WITHIN THE PAST 120 DAYS. ANTICONVULSANTS APTIOM BANZEL FYCOMPA OXTELLAR XR POTIGA QUDEXY
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Multiple Sclerosis Agents (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationAlly Rx D-SNP Current as of r 1, 2017
Ally Rx D-SNP Current as of r 1, 2017 AMPYRA AMPYRA PA Moderate to severe renal impairment (CrCL less than or equal to 50ml/min), patient not able to walk 25 feet in 8-45 seconds. Documentation of diagnosis,
More informationNB Drug Plans Formulary Update
Bulletin #980 August 23, 2018 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective August 23, 2018. Included in this bulletin: Regular Benefit Additions Special
More informationPharmacy and Medical Guideline Updates
STAT Bulletin PO Box 15013 Albany, New York 12212 August 2, 2010 Volume 8: Issue 19 To: All PCPs and Specialists Contracts Affected: All Lines of Business Pharmacy and ical Guideline Updates As a result
More informationHarvard Pilgrim Health Care Stride SM Basic Rx (HMO), Stride SM Value Rx (HMO) and Stride SM Value Rx Plus (HMO) Prior Authorization Requirements
Harvard Pilgrim Health Care Stride SM Basic Rx (HMO), Stride SM Value Rx (HMO) and Stride SM Value Rx Plus (HMO) Prior Authorization Requirements Effective /1/2018 Updated 7/2018 ACTEMRA ACTEMRA PA Age
More informationBENEFIT CHANGES TO NBPDP
Bulletin #789 June 15, 2010 BENEFIT CHANGES TO NBPDP This update to the New Brunswick Prescription Drug Program (NBPDP) Formulary is effective June 15, 2010. Included in this bulletin: Regular Benefit
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization MERC CARE (MEDICAID) Multiple Sclerosis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationMedicine Condition being treated NHSGGC Decision Date of decision. 18 June 2018 Page 1 of 5
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
More informationIntron A Hepatitis C. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.05 Subject: Intron A Hepatitis C Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Hepatitis
More information2017 Prior Authorization (PA) Criteria
2017 Prior Authorization (PA) Certain drugs require prior authorization from GuildNet Gold Plus FIDA Plan Medicare Plans. This means that your doctor must contact us to get approval before prescribing
More informationCARE N CARE HEALTH PLAN
PPI DEXILANT CAPSULE DELAYED RELEASE 30 MG ORAL DEXILANT CAPSULE DELAYED RELEASE 60 MG ORAL Claim will pay automatically for Dexilant if enrollee has a paid claim for at least a 1 days supply of lansoprazole,
More informationAntipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients
Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Preferred Agents (Oral) a Amitriptyline/Perphenazine (Generic) Aripiprazole Tablet (Generic) b Chlorpromazine
More informationSpecialty Overview by Prior Authorization Approval or Denial 4th Quarter 2016
Specialty Overview by Prior Authorization Approval or 4th Quarter 2016 Carrier Physician Specialty Drug Drug Class Decision Comments Reporting Year Reporting Month 3961 GASTROENTEROLOGY Humira RHEUMATOID
More informationINDICATIONS Treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload) EXJADE (deferasirox) is indicated for the
INDICATIONS Treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload) EXJADE (deferasirox) is indicated for the treatment of chronically elevated levels of iron in the
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationExjade (tablets for oral suspension), Jadenu (deferasirox)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.99.02 Subject: Exjade Jadenu Page: 1 of 5 Last Review Date: December 2, 2016 Exjade Jadenu Description
More informationAETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA)
AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA) Drugs Covered Procrit Epogen Aranesp Authorization guidelines For patients who meet all of the following: Does
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Self Administered Oncology Agents Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH VIRGIIA Multiple Sclerosis Agents (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More information2018 PRIOR AUTHORIZATION CRITERIA TABLE OF CONTENTS
2018 PRIOR AUTHORIZATION CRITERIA TABLE OF CONTENTS ADASUVE...26 ADCIRCA...13 ADEMPAS...15 AFINITOR... 149 AFINITOR DISPERZ... 149 ALECENSA... 149 ALUNBRIG... 149 amabelz tablet...98 AMITIZA...18 amitriptyline
More informationMETABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST
PRIOR AUTHORIZATION LIST (SUBJECT TO CHANGE) MEDICATION THERAPEUTIC CATEGORY MODULE ACTEMRA INFLAMMATORY CONDITIONS ACTEMRA ADCIRCA PULMONARY HYPERTENSION PDE-5 INHIBITORS FOR PAH ADDYI SEXUAL DISORDERS
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
More informationANTICONVULSANTS. Details
ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET APTIOM 800 MG TABLET BANZEL 200 MG TABLET BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG TABLET FYCOMPA 0.5 MG/ML ORAL SUSPENSION
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) Epoetin alfa (Epogen, Procrit ) Darbepoetin alfa (Aranesp ) Methoxy polyethylene glycol (PEG) epoetin-beta (Mircera ) Non-Discrimination Statement and Multi-Language
More informationSomavert ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Prior Authorization Requirements Effective March 1, 2019 ACROMEGALY THERAPY Somatuline Depot subcutaneous syringe 120 mg/0.5 ml, 60 mg/0.2 ml, 90 mg/0.3 ml Somavert Other Details PATIENT PROGRESS NOTES,
More informationDrug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs)
Drug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs) Line of Business: Medicaid P & T Approval Date: May 16, 2018 Effective Date: July 1, 2018 This policy has been developed
More informationANTICONVULSANTS. Details
ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension
More informationAetna Better Health of Illinois Medicaid Formulary Updates
October 2017 o DOXYLAMINE SUCCINATE 25mg-QL o DULOXETINE CAP 40MG DR-QL o GUANFACIN ER TABS (all strengths)-ql o TOBRAMYCIN NEBU SOLUTION- PA August 2017 Aetna Better Health of Illinois Medicaid 2017 Formulary
More informationSomavert ALL FDA-APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
ACROMEGALY THERAPY Somatuline Depot subcutaneous syringe 120 mg/0.5 ml, 60 mg/0.2 ml, 90 mg/0.3 ml Somavert Age Other ALL FDA-APPROVED INDICATIONS NOT OTHERWISE PATIENT PROGRESS NOTES, DOCUMENTATION OF
More informationLIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT
LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT The following medications may be covered under your medical benefit if they are provided to you in your doctor s office or outpatient infusion
More informationANTICONVULSANTS. Details
ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension
More informationHEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria
GLP1-INSULIN XULTOPHY SOLUTION PEN- INJECTOR 100-3.6 UNIT-MG/ML Claim will pay automatically for Xultophy if enrollee has a paid claim for at least a one day supply for step level 1 agent (LANTUS, LEVEMIR,
More informationACTHAR HP GEL PA MEDICATION(S) H.P. ACTHAR. COVERED USES All FDA-approved indications not otherwise excluded from Part D. EXCLUSION CRITERIA N/A
ACTHAR HP GEL PA H.P. ACTHAR Criteria for approval are ALL of the following: 1. ONE of: A. Diagnosis of infantile spasm OR B. Diagnosis of multiple sclerosis AND i. Patient is experiencing an acute exacerbation
More informationSutent. Sutent (sunitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.95 Subject: Sutent Page: 1 of 6 Last Review Date: March 16, 2018 Sutent Description Sutent (sunitinib)
More informationHEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria
GLP1-INSULIN XULTOPHY SOLUTION PEN- INJECTOR 100-3.6 UNIT-MG/ML HEALTHTEAM ADVANTAGE Claim will pay automatically for Xultophy if enrollee has a paid claim for at least a one day supply for step level
More information8-MOP. Products Affected
2018 First Choice VIP Care Plus Document: 2018 Prior Authorization Formulary ID: 18395 Last Updated: 10/2018 Effective Date: 11-01-2018 8-MOP 8-MOP Age must be a dermatologist or an oncologist. 1 ABILIFY
More informationGuidelines for Management of Chronic Conditions
Guidelines for Management of Chronic Conditions 1. DIABETES: If you have high blood sugar or Diabetes, the following are recommended: Goals to prevent progression of diabetes and reducing complications
More informationAntipsychotic Medications Age and Step Therapy
Market DC *- Florida Healthy Kids Antipsychotic Medications Age and Step Therapy Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Virginia Medicaid See State Specific Mandates *Indiana
More information